Delta-like protein 4 (DLL4), also known as Drosophila Delta homolog 4 (Delta4), contains one DSL domain and eight EGF-like domains. It is expressed in vascular endothelium and functions as a Notch ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the ...

Delta-like protein 4 (DLL4), also known as Drosophila Delta homolog 4 (Delta4), contains one DSL domain and eight EGF-like domains. It is expressed in vascular endothelium and functions as a Notch ...

This company’s main candidates include tovecimig (CTX-009), a bispecific antibody targeting DLL4 and VEGF-A; CTX-471, a CD137 agonist; and CTX-10726, a PD-1 x VEGF-A bispecific antibody.

The BTC market is small and competitive, with existing approved therapies, posing a risk despite tovecimig's unique DLL4+ targeting. Recent stock surge due to CTX-471 trial announcement ...

with the drug potentially addressing a $1.4B U.S. market for 2L BTC and a $1.3B U.S. market for DLL4+ mCRC. The bank also sees a second drug candidate, CTX-10726, as potentially a "competitive ...

The stock is up significantly so far in 2025 due to it reporting 2024 results and its anticipated top-line Phase 2/3 data readout for COMPANION-002, which is evaluating tovecimig (CTX-009, a DLL4 ...

The stock is up significantly so far in 2025 due to it reporting 2024 results and its anticipated top-line Phase 2/3 data readout for COMPANION-002, which is evaluating tovecimig (CTX-009, a DLL4 ...

By transiently blocking the heartbeat of E9.5 mouse embryos, we found that Notch activation in the arterial endothelium was dependent on its ligand Dll4, whereas the reduced expression of Dll4 in the ...